128 related articles for article (PubMed ID: 37279162)
1. Discovery of the First Potent, Selective, and
Sun Y; Xue Y; Sun P; Mu S; Liu H; Sun Y; Wang L; Wang J; Wu T; Yin W; Qin Q; Sun Y; Liu N; Wang H; Yang H; Zhao D; Cheng M
J Med Chem; 2023 Jun; 66(12):8200-8221. PubMed ID: 37279162
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer.
Sun Y; Sun Y; Wang L; Wu T; Yin W; Wang J; Xue Y; Qin Q; Sun Y; Yang H; Zhao D; Cheng M
Eur J Med Chem; 2022 Aug; 238():114424. PubMed ID: 35576702
[TBL] [Abstract][Full Text] [Related]
3. TRIM37 controls cancer-specific vulnerability to PLK4 inhibition.
Meitinger F; Ohta M; Lee KY; Watanabe S; Davis RL; Anzola JV; Kabeche R; Jenkins DA; Shiau AK; Desai A; Oegema K
Nature; 2020 Sep; 585(7825):440-446. PubMed ID: 32908304
[TBL] [Abstract][Full Text] [Related]
4. Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer.
Yeow ZY; Lambrus BG; Marlow R; Zhan KH; Durin MA; Evans LT; Scott PM; Phan T; Park E; Ruiz LA; Moralli D; Knight EG; Badder LM; Novo D; Haider S; Green CM; Tutt ANJ; Lord CJ; Chapman JR; Holland AJ
Nature; 2020 Sep; 585(7825):447-452. PubMed ID: 32908313
[TBL] [Abstract][Full Text] [Related]
5. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.
Lei Q; Xiong L; Xia Y; Feng Z; Gao T; Wei W; Song X; Ye T; Wang N; Peng C; Li Z; Liu Z; Yu L
Cell Death Dis; 2018 Oct; 9(11):1066. PubMed ID: 30337519
[TBL] [Abstract][Full Text] [Related]
6. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Potent and Selective Degrader for USP7.
Pei Y; Fu J; Shi Y; Zhang M; Luo G; Luo X; Song N; Mi T; Yang Y; Li J; Zhou Y; Zhou B
Angew Chem Int Ed Engl; 2022 Aug; 61(33):e202204395. PubMed ID: 35691827
[TBL] [Abstract][Full Text] [Related]
8. TRIM37: a critical orchestrator of centrosome function.
Domínguez-Calvo A; Gönczy P; Holland AJ; Balestra FR
Cell Cycle; 2021 Dec; 20(23):2443-2451. PubMed ID: 34672905
[TBL] [Abstract][Full Text] [Related]
9. TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein.
Bhatnagar S; Gazin C; Chamberlain L; Ou J; Zhu X; Tushir JS; Virbasius CM; Lin L; Zhu LJ; Wajapeyee N; Green MR
Nature; 2014 Dec; 516(7529):116-20. PubMed ID: 25470042
[TBL] [Abstract][Full Text] [Related]
10. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
Hu J; Hu B; Wang M; Xu F; Miao B; Yang CY; Wang M; Liu Z; Hayes DF; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
J Med Chem; 2019 Feb; 62(3):1420-1442. PubMed ID: 30990042
[TBL] [Abstract][Full Text] [Related]
11. Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor.
Sun Y; Wang L; Sun Y; Wang J; Xue Y; Wu T; Yin W; Qin Q; Sun Y; Wang H; Gao Y; Yang H; Zhao D; Cheng M
Eur J Med Chem; 2022 Dec; 243():114714. PubMed ID: 36063666
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 in HER2+ Cell Lines.
Chan K; Sathyamurthi PS; Queisser MA; Mullin M; Shrives H; Coe DM; Burley GA
Bioconjug Chem; 2023 Nov; 34(11):2049-2054. PubMed ID: 37917829
[TBL] [Abstract][Full Text] [Related]
13. Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
Han X; Zhao L; Xiang W; Miao B; Qin C; Wang M; Xu T; McEachern D; Lu J; Wang Y; Metwally H; Yang CY; Kirchhoff PD; Wang L; Matvekas A; Takyi-Williams J; Wen B; Sun D; Ator M; Mckean R; Wang S
J Med Chem; 2023 Jul; 66(13):8822-8843. PubMed ID: 37382562
[TBL] [Abstract][Full Text] [Related]
14. TRIM37 Augments AP-2γ Transcriptional Activity and Cellular Localization via K63-linked Ubiquitination to Drive Breast Cancer Progression.
Cui G; Gao Z; Chang S; Narwade N; Chen Y; Poudel B; Lei KMK; Zhang W; Li G; Poon TCW; Cheung E
Int J Biol Sci; 2022; 18(11):4316-4328. PubMed ID: 35864973
[TBL] [Abstract][Full Text] [Related]
15. Discovery of the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degrader for the Treatment of Pancreatic Cancer.
Sun N; Kabir M; Lee Y; Xie L; Hu X; Velez J; Chen X; Kaniskan HÜ; Jin J
J Med Chem; 2023 Jan; 66(1):596-610. PubMed ID: 36538511
[TBL] [Abstract][Full Text] [Related]
16. Global cellular response to chemical perturbation of PLK4 activity and abnormal centrosome number.
Tkach JM; Philip R; Sharma A; Strecker J; Durocher D; Pelletier L
Elife; 2022 Jun; 11():. PubMed ID: 35758262
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer.
Yu X; Li D; Kottur J; Kim HS; Herring LE; Yu Y; Xie L; Hu X; Chen X; Cai L; Liu J; Aggarwal AK; Wang GG; Jin J
J Med Chem; 2023 Dec; 66(23):16168-16186. PubMed ID: 38019706
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.
Yu X; Xu J; Shen Y; Cahuzac KM; Park KS; Dale B; Liu J; Parsons RE; Jin J
J Med Chem; 2022 Feb; 65(4):3644-3666. PubMed ID: 35119851
[TBL] [Abstract][Full Text] [Related]
19. Bivalent Ligands for Protein Degradation in Drug Discovery.
Scheepstra M; Hekking KFW; van Hijfte L; Folmer RHA
Comput Struct Biotechnol J; 2019; 17():160-176. PubMed ID: 30788082
[TBL] [Abstract][Full Text] [Related]
20. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
